{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:41:07Z","timestamp":1791380467364,"version":"4.3.3"},"reference-count":26,"publisher":"MedWorks Media","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>CYP2D6 subfamily isoenzymes play an important role in the biotransformation of haloperidol, and their activity may influence the efficacy and safety of haloperidol. The use of haloperidol is often associated with the occurrence of adverse drug reactions (ADRs), such as dyskinesia, acute dystonia, and orthostatic hypotension. Previous studies have demonstrated the relationship between the CYP2D64 genetic polymorphism and CYP2D6 activity, as well as haloperidol efficacy and safety rates. Purpose: To evaluate the association of CYP2D64 genetic polymorphism with the steady-state concentration of haloperidol in patients with acute alcohol-induced psychotic disorders (AIPDs). Material and methods: The study involved 100 male patients with AIPD (average age 41.4 \u00b1 14.4 years) who received haloperidol by injections in a dose of 5\u201310 mg\/day.<\/jats:p>","DOI":"10.64719\/pb.4450","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"52-60","source":"Crossref","is-referenced-by-count":1,"title":["Association of CYP2D6*4 Polymorphism with the Steady- State Concentration of Haloperidol in Patients with Alcohol-Induced Psychotic Disorders"],"prefix":"10.64719","volume":"52","author":[{"given":"AA","family":"Parkhomenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MS","family":"Zastrozhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SA","family":"Pozdnyakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VV","family":"Noskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IA","family":"Zaytsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VA","family":"Ivanchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NP","family":"Denisenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KA","family":"Akmalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V Yu","family":"Skryabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EA","family":"Bryun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DA","family":"Sychev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Masood B, Lepping P, Romanov D, Poole R. Treatment of Alcohol-Induced Psychotic Disorder (Alcoholic Hallucinosis)-A Systematic Review. Alcohol Alcohol. 2018;53(3):259\u2013267. doi: 10.1093\/alcalc\/agx090. doi:","DOI":"10.1093\/alcalc\/agx090"},{"key":"ref2","unstructured":"Egorov AY, Aleksin DS, Petrova NN. Specific features of alcoholic psychosis in psychiatric practice. Medicine. 2012;1:29\u201340. Vestnik of Saint Petersburg University."},{"key":"ref3","unstructured":"Kuzminov VN. Some aspects of the pathogenesis, clinic and treatment of delirium tremens. International Medical Journal. 2002;8(1\u20132):75\u201378."},{"key":"ref4","unstructured":"Mostovoy SM. Dynamics of prevalence of alcoholism and alcohol-related psychoses in the Far East. Russian Journal of Psychiatry. 2002;4:45\u201348."},{"key":"ref5","unstructured":"Nemkova TI, Gofman AG. Changes in the clinical picture of acute alcoholic hallucinosis over the past 50 years. Social and clinical psychiatry. 2018;28(2):25\u201329."},{"key":"ref6","unstructured":"Gofman AG. Medical Information Agency. Moscow: 2019. Alcoholic hallucinosis; p. 464."},{"key":"ref7","unstructured":"Sivolap YP, Savchenkov VA. Medicine. Moscow: 2001. Pharmacotherapy in narcology; p. 352."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Fan L, Tan L, Chen Z, Qi J, Nie F, Luo Z, Cheng J, Wang S. Haloperidol bound D2 dopamine receptor structure inspired the discovery of subtype selective ligands. Nat Commun. 2020;11(1):1074. doi: 10.1038\/s41467-020-14884-y. doi:","DOI":"10.1038\/s41467-020-14884-y"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Ohno Y, Kunisawa N, Shimizu S. Antipsychotic treatment of behavioral and psychological symptoms of dementia (BPSD): Management of extrapyramidal side effects. Front Pharmacol. 2019;10:1045. doi: 10.3389\/fphar.2019.01045. doi:","DOI":"10.3389\/fphar.2019.01045"},{"key":"ref10","unstructured":"Rahman S, Marwaha R. Treasure Island (FL): StatPearls Publishing; 2021. Haloperidol. StatPearls [Internet]"},{"key":"ref11","unstructured":"Nasyrova RF, Ivanov MV, Neznanov NG. St. Petersburg: Publishing center of the St. Petersburg V.M. Bekhterev Research Institute; 2015. Introduction to psychopharmacogenetics; p. 272."},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Eum S, Lee AM, Bishop JR. Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialog Clin Neurosci. 2016;18(3):323\u2013337. doi: 10.31887\/DCNS.2016.18.3\/jbishop. doi:","DOI":"10.31887\/DCNS.2016.18.3\/jbishop"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Spina E, De Leon J. Clinical applications of CYP genotyping in psychiatry. J Neural Transm. 2015;122(1):5\u201328. doi: 10.1007\/s00702-014-1300-5. doi:","DOI":"10.1007\/s00702-014-1300-5"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Gopisankar MG. CYP2D6 pharmacogenomics. Egypt J Med Hum Genet. 2017;18:309\u2013313. doi: 10.1016\/j.ejmhg.2017.03.001. doi:","DOI":"10.1016\/j.ejmhg.2017.03.001"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Williams IS, Gatchie L, Bharate SB, Chaudhuri B. Biotransformation, using recombinant CYP450-expressing baker\u2019s yeast cells, identifies a novel cyp2d6.10 a122v variant which is a superior metabolizer of codeine to morphine than the wild-type enzyme. ACS Omega. 2018;3:8903\u20138912. doi: 10.1021\/acsomega.8b00809. doi:","DOI":"10.1021\/acsomega.8b00809"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Jarvis JP, Peter AP, Shaman JA. Consequences of CYP2D6 copy-number variation for pharmacogenomics in psychiatry. Front Psychiatry. 2019;10:1\u201314. doi: 10.3389\/fpsyt.2019.00432. doi:","DOI":"10.3389\/fpsyt.2019.00432"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Zanger U, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Arch Pharmacol. 2004;369(1):23\u201337. doi: 10.1007\/s00210-003-0832-2. Naunyn Schmiedebergs. doi:","DOI":"10.1007\/s00210-003-0832-2"},{"key":"ref18","unstructured":"Fursa OO, Kozlovsky VL. Pharmacogenetic features of cytochrome P450 system activity in metabolism of antipsychotic drugs. Journal of Neurology and Psychiatry. 2014;4:111\u2013122."},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Nofziger C, Turner AJ, Sangkuhl K, Whirl-Carrillo M, Ag\u00fandez JAG, Black JL, Dunnenberger HM, Ruano G, Kennedy MA, Phillips MS, Hachad H, Klein TE, Gaedigk A. PharmVar GeneFocus: CYP2D6. Clin Pharmacol Ther. 2020;107(1):154\u2013170. doi: 10.1002\/cpt.1643. doi:","DOI":"10.1002\/cpt.1643"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, Scott SA, Rehm HL, Williams MS, Klein TE, Relling MV, Hoffman JM. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC) Genet Med. 2017;19(2):215\u2013223. doi: 10.1038\/gim.2016.87. doi:","DOI":"10.1038\/gim.2016.87"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner RM. A review of the important role of CYP2D6 in pharmacogenomics. Genes. 2020;11(11):1295. doi: 10.3390\/genes11111295. doi:","DOI":"10.3390\/genes11111295"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Kawanishi C, Furuno T, Kishida I, Matsumura T, Kosaka K. A patient with treatment-resistant schizophrenia and cytochrome P4502D6 gene duplication. Clin Genet. 2002;61(2):152\u2013154. doi: 10.1034\/j.1399-0004.2002.610211. doi:","DOI":"10.1034\/j.1399-0004.2002.610211"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. Acta Psychiatr Scand Suppl. 1987;334:1\u2013100. doi: 10.1111\/j.1600-0447.1987.tb10566. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. doi:","DOI":"10.1111\/j.1600-0447.1987.tb10566"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;212:11\u201319. doi: 10.1111\/j.1600-0447.1970.tb02066.x. doi:","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Parkhomenko AA, Zastrozhin MS, Skryabin V, Ivanchenko VA, Pozdniakov SA, Noskov VV, Zaytsev IA, Denisenko NP, Akmalova KA, Bryun EA, Sychev DA. Correlation of 1846G>A Polymorphism of CYP2D6 Gene with Haloperidol Efficacy and Safety in Patients with Alcoholic Hallucinoses. Psychopharmacol Bull. 2022 Jun 27;52(3):58\u201367.","DOI":"10.64719\/pb.4444"},{"key":"ref26","unstructured":"Annotation of DPWG Guideline for haloperidol and CYP2D6. Available at https:\/\/api.pharmgkb.org\/v1\/download\/file\/attachment\/DPWG_May_2021.pdf."}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:31:23Z","timestamp":1791315083000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/association-of-cyp2d64-polymorphism-with-the-steady-state-concentration-of-haloperidol-in-patients-with-alcohol-induced-psychotic-disorders\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4450","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}